Kerendia (finerenone) is the first and only non-steroidal mineralocorticoid receptor antagonist (nsMRA)
approved for adult patients with HF LVEF
>
40%
. By selectively blocking MR overactivation, Kerendia addresses early and sustained disease drivers to reduce the risk of cardiovascular (CV) death
and HF hospitalization
.
Every patient touchpoint represents an opportunity to initiate treatment4. Whether a patient is newly diagnosed
, attending a scheduled follow-up
, or has been recently hospitalized
, adding Kerendia 10mg or 20mg to a multimodal strategy provides proven risk reduction regardless of comorbidities or prior treatment. Given that 2 in 3 patients are rehospitalized within one year of discharge, making Kerendia a core pillar of care is essential for keeping patients out of the hospital and improving longevity
